PMA P150013S017

Device
PD-L1 IHC 22C3 pharmDx
Applicant
Agilent Technologies, Inc.
PMA number
P150013
Supplement
S017
Product code
PLS
Decision date
2020-03-19
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Approval order statement
Approved to migrate the PD-L1 IHC 22C3 pharmDx assay for NSCLC indication for use on the Dako Omnis automated staining system per approval letter.

Current openFDA PMA Record#

Device
PD-L1 IHC 22C3 pharmDx
Applicant
Agilent Technologies, Inc.
PMA number
P150013
Supplement
S017
Product code
PLS
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Decision date
2020-03-19
Decision code
APPR
Date received
2019-06-14
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Approval order statement
Approved to migrate the PD-L1 IHC 22C3 pharmDx assay for NSCLC indication for use on the Dako Omnis automated staining system per approval letter.